Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recent progress and strategic developments. The company is advancing two clinical trials for lead candidate ENV105 in prostate and EGFR-dependent non-small cell lung cancers, with safety and interim efficacy results expected in Q2 2025. Kairos is also developing KROS101, an immune response modulator, with recent data presented at key oncology conferences. Supported by non-dilutive government grants, an expanding trial network, and analyst coverage from firms including EF Hutton and HC Wainwright, Kairos emphasized its strong financial position and robust IP portfolio extending into the 2030s.

To view the full press release, visit https://ibn.fm/DVh1O

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit the company’s website at www.KairosPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

This press release is distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research.